Signaling transduction mechanisms mediating biological actions of the vascular endothelial growth factor family

Cardiovascular Research

Volumn 49, Issue 3, 2001, Pages 568-581

  Zachary, Ian ^a   Gliki, Georgia ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Angiogenesis; Apoptosis; Endothelial receptors; KDR; Nitric oxide; Prostaglandins; Signal transduction

Indexed keywords

FOCAL ADHESION KINASE; INTEGRIN; METALLOPROTEINASE; MITOGEN ACTIVATED PROTEIN KINASE; NEUROPILIN; NEUROPILIN 1; NITRIC OXIDE; PROSTACYCLIN; PROSTAGLANDIN; PROTEIN KINASE C; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL CELL; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; ENDOTHELIUM CELL; ENZYME ACTIVATION; ENZYME BINDING; ENZYME SYNTHESIS; HUMAN; HUMAN CELL; ISCHEMIC HEART DISEASE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; RECEPTOR BINDING; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; CAPILLARY PERMEABILITY; CELL DIVISION; CELL MOVEMENT; COLLATERAL CIRCULATION; DNA-BINDING PROTEINS; EARLY GROWTH RESPONSE PROTEIN 1; ENDOTHELIAL GROWTH FACTORS; ENDOTHELIUM, VASCULAR; EPOPROSTENOL; GENE EXPRESSION REGULATION; HUMANS; IMMEDIATE-EARLY PROTEINS; LYMPHOKINES; MILK PROTEINS; MYOCARDIAL ISCHEMIA; NEOVASCULARIZATION, PHYSIOLOGIC; NFATC TRANSCRIPTION FACTORS; NITRIC OXIDE; NUCLEAR PROTEINS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-ETS; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTORS, GROWTH FACTOR; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; STAT5 TRANSCRIPTION FACTOR; TRANS-ACTIVATORS; TRANSCRIPTION FACTORS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-3; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0035895711     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0008-6363(00)00268-6     Document Type: Review

References (161)

1. Vascular endothelial growth factor
2. Mechanisms of angiogenesis
3. Angiogenesis in cancer, vascular, rheumatoid and other diseases
4. Therapeutic angiogenesis for heart failure
5. Vascular protection: A novel, non-angiogenic cardiovascular role for vascular endothelial growth factor
6. Editorial: VEGF modulates NO production: The basis of a cytoprotective effect?
7. Human vascular permeability factor. Isolation from U937 cells
8. Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1
9. Overexpression of VEGF in testis and epididymis causes infertility in transgenic mice: Evidence for non-endothelial targets for VEGF
10. Vascular endothelial growth factor has neurotrophic activity and stimulates axonal outgrowth, enhancing cell survival and Schwann cell proliferation in the peripheral nervous system
11. VEGF couples hypertrophic cartilage remodeling, ossification and angiogenesis during endochondral bone formation
12. Signaling via vascular endothelial growth factor receptors
13. Vascular endothelial growth factor (VEGF) and its receptors
14. Similarities and differences between the vascular endothelial growth factor (VEGF) splice variants
15. 145, a secreted vascular endothelial growth factor isoform that binds to extracellular matrix
16. Extracellular cleavage of the vascular endothelial growth factor 189-amino acid form by urokinase is required for its mitogenic effect
17. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele
18. 188
19. Increased gene expression for VEGF and the VEGF receptors KDR/Flk and flt in lungs exposed to acute and chronic hypoxia. Modulation of gene expression by nitric oxide
20. Dimerization, DNA binding and transactivation properties of hypoxia inducible factor 1
21. Role of HIF-1 alpha in hypoxia mediated apoptosis, cell proliferation, and tumor angiogenesis
22. Systemic hypoxia changes the organ-specific distribution of vascular endothelial growth factor and its receptors
23. Indirect angiogenic cytokines upregulate VEGF and bFGF gene expression in vascular smooth muscle cells, whereas hypoxia upregulates VEGF expression only
24. Hypoxia and platelet-derived growth factor-BB synergistically upregulate the expression of vascular endothelial growth factor in vascular smooth muscle cells
25. Basic fibroblast growth factor upregulates the expression of vascular endothelial growth factor in vascular smooth muscle cells
26. Induction of macrophage VEGF in response to oxidised LDL and VEGF accumulation in human atherosclerotic lesions
27. Induction of vascular endothelial growth factor gene expression by interleukin-1β in rat aortic smooth muscle cells
28. Stretch-induced VEGF expression in the heart
29. Genomic organization of the mouse and human genes for vascular endothelial growth factor B (VEGF-B) and characterization of a second splice isoform
30. Two alternative mRNAs coding for the angiogenic factor, placenta growth factor (PlGF), are transcribed from a single gene of chromosome 14
31. Proteolytic processing regulates receptor specificity and activity of VEGF-C
32. Hyperplasia of lymphatic vessels in VEGF-C transgenic mice
33. VEGF-C receptor binding and pattern of expression with VEGFR-3 suggests a role in lymphatic vascular development
34. Mice lacking the vascular endothelial growth factor-B gene (VEGF-B) have smaller hearts, dysfunctional coronary vasculature, and impaired recovery from cardiac ischemia
35. Current biology of VEGF-B and VEGF-C
36. Vascular endothelial growth factor B (VEGF-B) binds to VEGF receptor-1 and regulates plasminogen activator activity in endothelial cells
37. Placenta growth factor: Potential role in pregnancy
38. In vivo angiogenic activity and hypoxia induction of heterodimers of placenta growth factor/endothelial growth factor
39. A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases
40. Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4)
41. Placenta growth factor. Potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo, and high affinity binding to Flt-1 but not Flk-1/KDR
42. A novel type of vascular endothelial growth factor, VEGF-E (NZ-7 VEGF), preferentially utilizes KDR/Flk-1 receptor and carries a potent mitotic activity without heparin-binding domain
43. The vascular endothelial growth factor receptor Flt-1 mediates biological activities. Implications for a functional role of placenta growth factor in monocyte activation and chemotaxis
44. The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor
45. High affinity binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis
46. Different signal transduction properties of KDR and Flt-1, two receptors for vascular endothelial growth factor
47. Vascular endothelial growth factor: Crystal structure and functional mapping of the kinase domain receptor binding site
48. The second immunoglobulin-like domain of the VEGF tyrosine kinase receptor Flt-1 determines ligand binding and may initiate a signal transduction cascade
49. Requirements for binding and signaling of the kinase domain receptor for vascular endothelial growth factor
50. Identification of the residues in the extracellular region of the KDR important for the interaction with the vascular endothelial growth factor and neutralizing anti-KDR antibodies
51. Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice
52. Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium
53. Cardiovascular failure in mouse embryos deficient in VEGF receptor-3
54. Neuropilin-1 is expressed by endothelial and tumour cells as an isoform-specific receptor for vascular endothelial growth factor
55. Differential binding of vascular endothelial growth factor B splice and proteolytic isoforms to neurophilin-1
56. Neuropilin 1 is a placental growth-2 receptor
57. Collapsin: A protein in brain that induces the collapse and paralysis of neuronal growth cones
58. Overexpression of a membrane protein, neuropilin, in chimeric mice causes anomalies in the cardiovascular system, nervous system and limbs
59. A requirement for neuropilin-1 in embryonic vessel formation
60. Endothelial growth factor receptors in human fetal heart
61. 121, a vascular endothelial growth factor (VEGF) isoform lacking heparin binding ability, requires cell surface heparan sulfates for efficient binding to the VEGF receptors of human melanoma cells
62. Glypican-1 is a VEGF165 binding proteoglycan that acts as an extracellular chaperone for VEGF165
63. The phosphorylated 1169-tyrosine containing region of flt-1 kinase (VEGFR-1) is a major binding site for PLCgamma
64. A unique signal transduction from FLT tyrosine kinase, a receptor for vascular endothelial growth factor VEGF
65. Placenta growth factor stimulates MAP kinase and mitogenicity, but not phospholipase C-γ and migration of endothelial cells expressing Flt-1
66. Role of VEGF receptor-1 (Flt-1) in mediating calcium-dependent nitric oxide release and limiting DNA synthesis in human trophoblast cells
67. 2+ mobilization in human umbilical vein endothelial cells
68. Interaction of the Flt-1 tyrosine kinase receptor with the p85 subunit of phosphatidylinositol 3-kinase. Mapping of a novel site involved in binding
69. Vascular endothelial growth factor upregulates the expression of matrix metalloproteinases in vascular smooth muscle cells. Role of Flt1
70. Flt-1 lacking the tyrosine kinase domain is sufficient for normal development and angiogenesis in mice
71. Inhibition of vascular endothelial growth factor activity by an endogenously encoded soluble receptor
72. Differential binding characteristics and cellular inhibition by soluble VEGF receptors 1 and 2
73. Receptor chimeras indicate that the vascular endothelial growth factor receptor 1 (VEGFR-1) modulates mitogenic activity of VEGFR-2 in endothelial cells
74. A repressor sequence in the juxtamembrane domain of Flt-1 (VEGFR1) constitutively inhibits vascular endothelial growth factor-dependent phosphatidylinositol 3′-kinase activation and endothelial cell migration
75. Biological activity and phosphorylation sites of the bacterially expressed cytosolic domain of the KDR VEGF-receptor
76. Vascular endothelial cell growth factor promotes tyrosine phosphorylation of mediators of signal transduction that contain SH2 domains
77. The vascular endothelial growth factor receptor KDR activates multiple signal transduction pathways in porcine aortic endothelial cells
78. HCPTPA, a protein tyrosine phosphatase that regulates vascular endothelial growth factor receptor-mediated signal transduction and biological activity
79. 2 in endothelial cells via p42/p44 mitogen activated protein kinases
80. A novel function of the vascular endothelial growth factor receptor-2 (KDR): Rapid release of nitric oxide in response to VEGF-A stimulation in endothelial cells
81. Vascular endothelial growth factor governs endothelial nitric-oxide synthase expression via a KDR/Flk-1 receptor and protein kinase C signaling pathway
82. The 230-kDa mature form of KDR/Flk-1 (VEGF receptor-2) activates the PLC-gamma pathway and partially induces mitotic signals in NIH3T3 cells
83. Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3′-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation
84. Vascular endothelial growth factor signals endothelial cell production of nitric oxide and prostacyclin through Flk-1/KDR activation of c-Src
85. Vascular endothelial growth factor C induces angiogenesis in vivo
86. A recombinant mutant vascular endothelial growth factor-C that has lost vascular endothelial growth factor receptor-2 binding, activation, and vascular permeability activities
87. Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity
88. The role of phosphatidylinositol 3′-kinase in vascular endothelial growth factor signaling
89. Vascular endothelial growth factor induces expression of the antiapoptotic proteins Bcl-2 and A1 in vascular endothelial cells
90. Marked induction of the IAP antiapoptotic proteins survivin and XIAP by VEGF in vascular endothelial cells
91. FAK): A point of convergence in the action of neuropeptides, integrins and oncogenes
92. Extracellular matrix survival signals transduced by focal adhesion kinase suppress p53-mediated apoptosis
93. Caspase-mediated cleavage of focal adhesion kinase pp125FAK and disassembly of focal adhesions in human endothelial cell apoptosis
94. Vascular endothelial growth factor stimulates tyrosine phosphorylation and recruitment to new focal adhesions of focal adhesion kinase and paxillin in endothelial cells
95. Vascular endothelial growth factor (VEGF)-driven actin-based motility is mediated by VEGFR2 and requires concerted activation of stress-activated protein kinase 2 (SAPK2/p38) and geldanamycin-sensitive phosphorylation of focal adhesion kinase
96. Utilization of distinct signaling pathways by receptors for vascular endothelial growth factor and other mitogens in the induction of endothelial cell proliferation
97. Characterization of signal transduction pathways in human bone marrow endothelial cells
98. 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels
99. 3 integrin in the activation of vascular endothelial growth factor receptor-2
100. β3-Integrin-deficient mice are a model for Glanzmann thrombasthenia showing placental defects and reduced survival
101. 1 integrins
102. Distinct signal transduction pathways are utilized during the tube formation and survival phases of in vitro angiogenesis
103. ERK/JUN kinase cross-talk underlies vascular endothelial cell growth factor-induced endothelial cell proliferation
104. Characterization of vascular endothelial growth factor's effect on the activation of protein kinase C, its isoforms, and endothelial cell growth
105. The proliferative effect of vascular endothelial growth factor requires protein kinase C-α and protein kinase C-ζ
106. A role of protein kinase C in the regulation of cytosolic phospholipase A(2) in bradykinin-induced PGI(2) synthesis by human vascular endothelial cells
107. VEGF activates protein kinase C-dependent, but Ras-independent Raf-MEK-MAP kinase pathway for DNA synthesis in primary endothelial cells
108. Vascular endothelial growth factor induced endothelial cell migration and proliferation depend on a nitric oxide-mediated decrease in protein kinase Cδ activity
109. Enhancement of migration by protein kinase alpha and inhibition of proliferation and cell cycle progression by protein kinase C delta in capillary endothelial cell
110. Mitogen-activated protein kinase pathways
111. VEGF stimulates MAPK through a pathway that is unique for receptor tyrosine kinases
112. 2+
113. Nitric oxide is an upstream signal of vascular endothelial growth factor-induced extracellular-signal-regulated kinase1/2 activation in postcapillary endothelium
114. Protein kinase G mediates vascular endothelial growth factor-induced Raf-1 activation and proliferation in human endothelial cells
115. Vascular endothelial growth factor increases release of gelatinase A and decreases release of tissue inhibitor of metalloproteinases by microvascular endothelial cells in vitro
116. Signaling mechanisms in the regulation of vascular cell migration
117. p38 MAP kinase activation by vascular endothelial growth factor mediates actin reorganization and cell migration in human endothelial cells
118. Permissive role of nitric oxide in endothelin-induced migration of endothelial cells
119. Nitric oxide modulation of focal adhesions in endothelial cells
120. Nitric oxide synthase lies downstream from vascular endothelial growth factor-induced but not basic fibroblast growth factor-induced angiogenesis
121. Nitric oxide production contributes to the angiogenic properties of vascular endothelial growth factor in human endothelial cells
122. Phosphorylation of the endothelial nitric oxide synthase at Ser-1177 is required for VEGF-induced endothelial cell migration
123. Vascular endothelial growth factor stimulates protein kinase C-dependent phospholipase D activity in endothelial cells
124. Vascular endothelial growth factor induces EDRF-dependent relaxation in coronary arteries
125. VEGF gene transfer reduces intimal thickening via increased production of nitric oxide in carotid arteries
126. Vascular endothelial growth factor/vascular permeability factor augments nitric oxide release from quiescent rabbit and human vascular endothelium
127. Reciprocal relation between VEGF and NO in the regulation of endothelial integrity
128. Vascular endothelial growth factor/vascular permeability factor enhances vascular permeability via nitric oxide and prostacyclin
129. Dynamic activation of endothelial nitric oxide synthase by Hsp 90
130. Vascular endothelial growth factor up-regulates nitric oxide synthase expression in endothelial cells
131. VEGF upregulates ecNOS message, protein, and NO production in human endothelial cells
132. Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation
133. Regulation of endothelium-derived nitric oxide production by the protein kinase Akt
134. Local delivery of vascular endothelial growth factor accelerates reendothelialization and attenuates intimal hyperplasia in balloon-injured rat carotid artery
135. Accelerated restitution of endothelial integrity and endothelial dependent function after phVEGF165 gene transfer
136. Vascular endothelial growth factor (VEGF) induces plasminogen activators and plasminogen activator inhibitor-1 in microvascular endothelial cells
137. 2+ and von Willebrand factor release in human endothelial cells
138. Cooperation between VEGF and TNF-alpha is necessary for exposure of active tissue factor on the surface of human endothelial cells
139. Role of tissue factor in embryonic blood vessel development
140. Von Willebrand factor promotes endothelial cell adhesion via an Arg-Gly-Asp-dependent mechanism
141. Vascular permeability factor: A tumor-derived polypeptide that induces endothelial cell and monocyte procoagulant activity, and promotes monocyte migration
142. The structure and function of the blood-brain barrier
143. Vascular endothelial growth factor induces endothelial fenestrations in vitro
144. Quantitative morphology of human glioblastoma multiforme microvessels: Structural basis of blood-brain barrier defect
145. Neovasculature induced by vascular endothelial growth factor is fenestrated
146. Hypoxia induces permeability in brain microvessel endothelial cells via VEGF and NO
147. Increased microvascular permeability and endothelial fenestrations induced by vascular endothelial growth factor
148. VEGF induces nuclear translocation of Flk-1/KDR, endothelial nitric oxide synthase, and caveolin-1 in vascular endothelial cells
149. Vesiculo-vacuolar organelles and the regulation of venule permeability to macromolecules by vascular permeability factor, histamine and serotonin
150. Ultrastructural localization of vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) to the abluminal plasma membrane and vesiculovacuolar organelles of tumor microvascular endothelium
151. Role of phospholipase C, protein kinase C, and calcium in VEGF-induced venular hyperpermeability
152. Endothelial adherens junctions: Implications in the control of vascular permeability and angiogenesis
153. Vascular endothelial growth factor induces VE-cadherin tyrosine phosphorylation in endothelial cells
154. VEGF stimulates tyrosine phosphorylation of β-catenin and small-pore endothelial barrier dysfunction
155. Vascular endothelial growth factor induces rapid phosphorylation of tight junction proteins, occludin and zona occluden 1. A potential mechanism for vascular permeability in diabetic retinopathy and tumors
156. A mutant form of vascular endothelial growth factor (VEGF) that lacks VEGF receptor-2 activation retains the ability to induce vascular permeability
157. Inhibition of vascular endothelial growth factor-induced migration by ETS1 antisense oligonucleotides
158. Vascular endothelial growth factor-induced tissue factor expression in endothelial cells is mediated by EGR-1
159. Vascular endothelial growth factor activates nuclear factor of activated T cells in human endothelial cells: A role for tissue factor gene expression
160. Endothelial receptor tyrosine kinases activate the STAT signaling pathway: Mutant Tie-2 causing venous malformations signals a distinct STAT activation response
161. Hypoxia and vascular endothelial growth factor selectively upregulate angiopoietin-2 in bovine microvascular endothelial cells